Abstract
Presenting Symptoms, Vaccination Status and Association Comorbidities in Confirmed Cases of COVID-19 in King Salman Army Forces Hospital North West Region, Tabuk City KSA
Sarah Almutairi*, Tariq Shaqra, Khalil Abujamilah, Abdullah Alhaje, Huda Alturabi, Maiada Mohamed, Tahani Khalil, Fatma Faraj, Amal Albalawi and Maha Alujeyli
Corresponding Author: Sarah Almutairi, Department of Family Medicine, King Salman Armed Forces Hospital, Tabuk, Kingdom of Saudi Arabia.
Revised: January 11, 2023; Available Online: January 11, 2023
Citation: Almutairi S, Shaqra T, Abujamilah K, Alhaje A, Alturabi H, et al. (2023) Presenting Symptoms, Vaccination Status and Association Comorbidities in Confirmed Cases of COVID-19 in King Salman Army Forces Hospital North West Region, Tabuk City KSA. J Infect Dis Res, 6(S1): 04.
Copyrights: ©2023 Almutairi S, Shaqra T, Abujamilah K, Alhaje A, Alturabi H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 29

    Views & Citations
Background: Most commonly reported symptoms for COVID-19 patients are anosmia, dysgeusia, cough, myalgias, and headache, with no specific clinical features that can reliably distinguish COVID-19 from other respiratory infections.

Objectives: To describe the most frequent presenting symptoms of COVID-19, guide case suspicion, based on clinical manifestations, and characterize case severity.

Patients and Methods: This was a retrospective descriptive hospital-based research design conducted at the Armed Forces Hospitals, Northwestern Region, in Tabuk City, Saudi Arabia among all adult patients aged ≥ 18 years who were admitted as confirmed cases of COVID-19. A data collection sheet was utilized including patients’ demographic data, presenting symptom(s) and their severity, vaccination status, and a history of recent contact with any confirmed case.

Results: A total of 300 patients with confirmed COVID-19 were included. Their age ranged from 18 and 85 years. Equally were distributed between males and females. History of travel in the last 14 days was mentioned by 9.7% of them while 71.3% reported contact with confirmed cases. Cough was the commonest reported symptom (49.3%), followed by fever (44%), headache (36.7%), sore throat (28.7%), and running nose (22%). Regarding vaccinated cases, the Pfizer-BioNTech vaccine ranked first (66%), followed by the AstraZeneca Oxford vaccine (23.9%) and both vaccines (8.1%). Multivariate logistic regression analysis revealed that patients who received a second dose of Pfizer-BioNTech or AstraZeneca Oxford vaccines were at lower risk for developing moderate/severe symptoms than those who received one dose, p=0.001 and 0.008; respectively.

Conclusion: Most cases of confirmed COVID-19 infection were mild. The vast majority of the participants had received the COVID-19 vaccine. Of them, the Pfizer-BioNTech vaccine ranked first, followed by the AstraZeneca Oxford vaccine and both vaccines. Patients who received a second dose of either AstraZeneca Oxford or Pfizer-BioNTech vaccines were at lower risk for developing moderate/severe symptoms than those who received one dose.

Keywords: COVID-19, Confirmed cases, Vaccines, Presenting symptoms, Severity